A nanoparticle loaded nasal sol-gel system of midazolam hydrochloride for the management of intermittent seizures

Articles in Press

Document Type : Research Paper

Authors

1 Department of Pharmaceutics, Krupanidhi College of Pharmacy, Bangalore, Karnataka, India

2 Department of Pharmacology, Oxford College of Pharmacy, Bangalore , Karnataka, India

3 Department of Pharmacology, Oxford College of Pharmacy, Bangalore, Karnataka, India

Abstract

Objective(s): Midazolam hydrochloride is a short-acting hypnotic sedative with anticonvulsant properties. Considering the poor bioavailability, rapid elimination, and inconvenience of administering oral medication in epileptic conditions, this study proposed the use of a nanoparticulate in situ nasal gel system for midazolam to achieve an optimum therapeutic effect.
Materials and Methods: Drug-loaded PLGA nanoparticles were prepared by an emulsion-solvent evaporation method utilizing a Box–Behnken design concentrated on particle size, zeta potential, and drug entrapment efficiency as responses. The optimized nanoparticles were incorporated into a 0.2% w/v gellan gum solution. The nanoparticle-loaded gel was studied for ex vivo drug permeation through excised sheep nasal mucosa. The anticonvulsive activity of the gel was compared with that of the marketed midazolam nasal spray (0.5 mg/0.1 ml).
Results: Particle size (200 nm to 310 nm), zeta potential (-25mV to -31mV), and entrapment efficiency (81.23±0.21 to 93.32±0.28%) were observed in the formulations. The drug release from the formulations over 24 h was found to be 75.32±0.028to 84.63±0.061%. Particle size and zeta potential were best fitted to the quadratic model, and an entrapment efficiency linear model was suggested. The ex vivo permeation studies of the optimized nanoparticle-incorporated gel formulation exhibited a fourfold increase in flux and permeability coefficient in comparison to the pure drug-incorporated gel. The anticonvulsive effect in pentylenetetrazol (PTZ)-induced rat model epilepsy showed a similar anticonvulsive profile to that of the marketed nasal spray.
Conclusion: Drug-loaded nanoparticles incorporated in situ gel would be a promising, biocompatible, and non-invasive approach to achieve the required therapeutic efficacy by sustained and direct action on brain cells

Keywords

References

  1. Manford M. Recent advances in epilepsy. J Neurol. 2017; 264(8):1811–1824.
  2. Olkkola KT, Ahonen J. Midazolam and other benzodiazepines. Modern Anesthetics. 2008:335-360.
  3. Cornett EM, Nemomsa MA, Turbeville B, Busby MA, Kaye JS, Kaye AJ, et al. Midazolam nasal spray to treat intermittent, stereotypic episodes of frequent seizure activity: pharmacology and clinical role, a comprehensive review. Health Psychol Res. 2022;10(5).
  4. Erdő F, Bors LA, Farkas D, Bajza Á, Gizurarson S et al. Evaluation of intranasal delivery route of drug administration for brain targeting. Brain Res bulletin. 2018; 143:155-170.
  5. Bonferoni MC, Rassu G, Gavini E, Sorrenti M, Catenacci L, Giunchedi P et al. Nose-to-brain delivery of antioxidants as a potential tool for the therapy of neurological diseases. Pharmaceutics. 2020; 12(12):1246.
  6. Patel S, Koradia H, Parikh R. Design, and development of intranasal in situ gelling system of Midazolam hydrochloride using 32 full factorial design. J Drug Deliv Sci and Technol. 2015; 30:154-162.
  7. Gholizadeh H, Cheng S, Pozzoli M, Messerotti E, Traini D, Young P, Kourmatzis A, Ong HX et al. Smart thermosensitive chitosan hydrogel for nasal delivery of ibuprofen to treat neurological disorders. Expert Opin Drug Deliv. 2019; 16 (4):453-466.
  8. Kapoor M, Cloyd JC, Siegel RA. A review of intranasal formulations for the treatment of seizure emergencies. J Controlled Release. 2016; 237:147-159.
  9. Su Y, Sun B, Gao X, Dong X, Fu L, Zhang Y, et al. Intranasal delivery of targeted nanoparticles loaded with miR-132 to brain for the treatment of neurodegenerative diseases. Front Pharmacol. 2020;11.
  10. Zeeshan M, Mukhtar M, Ul Ain Q, Khan S, Ali H. Nanopharmaceuticals: A Boon to the Brain-Targeted Drug Delivery, Pharmaceutical Formulation Design - Recent Practices. IntechOpen; 2020.
  11. Pal SL, Jana U, Manna PK, Mohanta GP, Manavalan R. Nanoparticle: An overview of preparation and characterization. J Applied Pharm Sci. 2011;(6):228-34.
  12. Formica ML, Real DA, Picchio ML, Catlin E, Donnelly RF, Paredes AJ. On a highway to the brain: A review on nose-to-brain drug delivery using nanoparticles. Appl Mater Today. 2022; 29(101631):101631.
  13. Islam SU, Shehzad A, Ahmed MB, Lee YS. Intranasal delivery of nanoformulations: A potential way of treatment for neurological disorders. Molecules. 2020;25(8):1929.
  14. Sonawane RO, Bachhav Y, Tekade AR, Pardeshi CV. Nanoparticles for direct nose-to-brain drug delivery: Implications of targeting approaches. In: Direct Nose-to-Brain Drug Delivery. Elsevier. 2021: 157–168.
  15. Nigam K, Kaur A, Tyagi A, Nematullah M, Khan F, Gabrani R, Dang S et al. Nose-to-brain delivery of lamotrigine-loaded PLGA nanoparticles. Drug Deliv Transl Res. 2019;9(5):879-890.
  16. Kızılbey K. Optimization of rutin-loaded PLGA nanoparticles synthesized by single-emulsion solvent evaporation method. ACS Omega. 2019;4(1):555–562.
  17. Joshi AS, Patel HS, Belgamwar VS, Agrawal A, Tekade AR. Solid lipid nanoparticles of ondansetron HCl for intranasal delivery: development, optimization and evaluation. J Mater Sci: Mater Med. 2012;23(9):2163-2175.
  18. Sharaf NS, Shetta A, Elhalawani JE, Mamdouh W. Applying Box–Behnken Design for formulation and optimization of PLGA-coffee nanoparticles and detecting enhanced antioxidant and anticancer activities. Polymers (Basel). 2021; 14(1):144.
  19. Wavikar PR, Vavia PR. Rivastigmine-loaded in situ gelling nanostructured lipid carriers for nose to brain delivery. J Liposome Res. 2015; 25(2):141-149.
  20. Abdel-Bar HM, Abdel-Reheem AY, Awad GA, Mortada ND. Evaluation of brain targeting and mucosal integrity of nasally administrated nanostructured carriers of a CNS active drug, clonazepam. J Phar & Pharm Sci. 2013; 16(3):456-469.
  21. Fahmy UA, Badr-Eldin SM, Ahmed OA, Aldawsari HM, Tima S, Asfour HZ, Al-Rabia MW, Negm AA, Sultan MH, Madkhali OA, Alhakamy NA et al. Intranasal niosomal in situ gel as a promising approach for enhancing flibanserin bioavailability and brain delivery: In vitro optimization and ex vivo/in vivo evaluation. Pharm. 2020;(6):485.
  22. Bhavna, Md, S., Ali, M., Ali, R., Bhatnagar, A., Baboota, S., & Ali, J, et al. brain targeting of Donepezil nanosuspension intended for nose: In vitro and in vivo safety evaluation. Int J Bio Macromol 2014; 67:418–425.
  23. Sherafudeen SP, Vasantha PV. Development and evaluation of in situ nasal gel formulations of loratadine. Res Pharm Sci. 2015; (6):466.
  24. Deshkar SS, Jadhav MS, Shirolkar SV. Development of carbamazepine nanostructured lipid carrier loaded Thermosensitive gel for intranasal delivery. Adv Pharm Bull. 2020; 11(1):150–162.
  25. Nogueira C, Lemos-Senna E, da Silva Vieira E, Sampaio TB, Mallmann MP, Oliveira MS, et al. Β-caryophyllene cationic nanoemulsion for intranasal delivery and treatment of epilepsy: Development and in vivo evaluation of anticonvulsant activity. J Nanopart Res. 2023; 25(1).
Nanomedicine Journal

Articles in Press, Accepted Manuscript
Available Online from 18 March 2025

Files

Share

How to cite

Statistics